Second generation direct-acting antivirals – Do we expect major improvements?

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages S130-S142

  Feld, Jordan J ^a   Foster, Graham R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chronic kidney disease (CKD); Cirrhosis; Direct acting antivirals; Genotype 3; Hepatitis C virus; Pan genotypic; Resistance associated variants; Salvage regimens

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTIVIRAL THERAPY; CHRONIC KIDNEY FAILURE; DECOMPENSATED LIVER CIRRHOSIS; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; KIDNEY FAILURE; LIVER TRANSPLANTATION; PATIENT CARE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; TREATMENT DURATION; CHRONIC HEPATITIS C; COMPLICATION; DRUG ADMINISTRATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; GENOTYPE; HEALTH CARE DELIVERY; HEPACIVIRUS; LIVER CIRRHOSIS; METABOLISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; TRENDS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DISCOVERY; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RENAL INSUFFICIENCY, CHRONIC; SALVAGE THERAPY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE;

EID: 85013484205     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.007     Document Type: Review

References (84)

1. [1] Dore, G.J., Feld, J.J., Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis 60 (2015), 1829–1836.
2. [2] Lamarre, D., Anderson, P.C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003), 186–189.
3. [3] Pawlotsky, J.M., Feld, J.J., Zeuzem, S., Hoofnagle, J.H., From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62 (2015), S87–S99.
4. [4] Kumar, S., Jacobson, I.M., Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. J Hepatol 61 (2014), S91–S97.
5. [5] Feld, J.J., Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 34 (2014), 37–46.
6. [6] Kirby, B.J., Symonds, W.T., Kearney, B.P., Mathias, A.A., Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 54 (2015), 677–690.
7. [7] Delang, L., Vliegen, I., Froeyen, M., Neyts, J., Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother 55 (2011), 4103–4113.
8. [8] Kati, W., Koev, G., Irvin, M., Beyer, J., Liu, Y., Krishnan, P., et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59 (2015), 1505–1511.
9. [9] Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465 (2010), 96–100.
10. [10] Guedj, J., Dahari, H., Rong, L., Sansone, N.D., Nettles, R.E., Cotler, S.J., et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110 (2013), 3991–3996.
11. [11] Nguyen, L.T., Hall, N., Sheerin, D., Carr, M., De Gascun, C.F., Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir Ther, 2016.
12. [12] Krishnan, P., Tripathi, R., Schnell, G., Reisch, T., Beyer, J., Dekhtyar, T., et al. Long-term follow-up of treatment-emergent resistance-associated vairantes in NS3, NS5A and NS5B with paritaprevir, ombitasvir and dasabuvir-based regimens. J Hepatol, 62, 2015, O057.
13. [13] Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J.M., Mallolas, J., Pol, S., et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1087–1097.
14. [14] Sulkowski, M.S., Vargas, H.E., Di Bisceglie, A.M., Kuo, A., Reddy, K.R., Lim, J.K., et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150 (2016), 419–429.
15. [15] Terrault, N.A., Zeuzem, S., Di Bisceglie, A.M., Lim, J.K., Pockros, P., Frazier, L.M., et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. Hepatology, 2015 Abstract AASLD November 2015, San Francisco.
16. [16] Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
17. [17] Alqahtani, S., Zeuzem, S., Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: internal analysis of a prospective observational study. J Hepatol, 2015 International Liver Congress (ILC), April 22–26, Vienna, Austria; abstract PO840.
18. [18] Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
19. [19] Leroy, V., Angus, P., Bronowicki, J.P., Dore, G.J., Hezode, C., Pianko, S., et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology, 2016.
20. [20] Welzel, T.M., Peterson, J., Ferenci, P., Gschwantler, M., Herzer, K., Cornberg, M., et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter european compassionate use program. Hepatology, 2015 Abstract AASLD 2015 San Francisco.
21. [21] Foster, G.R., Pianko, S., Brown, A., Forton, D., Nahass, R.G., George, J., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology, 2015.
22. [22] Pianko, S., Zeuzem, S., Chuang, W.L., Foster, G.R., Sarin, S.K., Flisiak, R., et al. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. J Viral Hepat 19 (2012), 623–634.
23. [23] Thompson, A.J., Patel, K., Chuang, W.L., Lawitz, E.J., Rodriguez-Torres, M., Rustgi, V.K., et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 61 (2012), 128–134.
24. [24] Clark, P.J., Thompson, A.J., Vock, D.M., Kratz, L.E., Tolun, A.A., Muir, A.J., et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56 (2012), 49–56.
25. [25] Younossi, Z.M., Stepanova, M., Estep, M., Negro, F., Clark, P.J., Hunt, S., et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol 64 (2016), 29–36.
26. [26] Al Marzooqi, S.H., Feld, J.J., Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 35 (2015), 1923–1933.
27. [27] Hussain, S., Barretto, N., Uprichard, S.L., New hepatitis C virus drug discovery strategies and model systems. Expert Opin Drug Discov 7 (2012), 849–859.
28. [28] Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
29. [29] Schnell, G., Tripathi, R., Beyer, J., Reisch, T., Krishnan, P., Lu, L., et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 59 (2015), 6807–6815.
30. [30] Asselah, T., Bourliere, M., Hepatitis C virus: current and evolving treatments for genotype 4. Gastroenterol Clin North Am 44 (2015), 859–870.
31. [31] Abergel, A., Asselah, T., Metivier, S., Kersey, K., Jiang, D., Mo, H., et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis, 2016.
32. [32] Poordad, F., Hezode, C., Trinh, R., Kowdley, K.V., Zeuzem, S., Agarwal, K., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
33. [33] Reddy, K.R., Bourliere, M., Sulkowski, M., Omata, M., Zeuzem, S., Feld, J.J., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
34. [34] Everson, G.T., Trotter, J., Forman, L., Kugelmas, M., Halprin, A., Fey, B., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 (2005), 255–262.
35. [35] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
36. [36] Welker, M.W., Luhne, S., Lange, C.M., Vermehren, J., Farnik, H., Herrmann, E., et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 64 (2016), 790–799.
37. [37] Dyson, J.K., Hutchinson, J., Harrison, L., Rotimi, O., Tiniakos, D., Foster, G.R., et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 64 (2016), 234–238.
38. [38] (FDA) FDA. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. In; 2015.
39. [39] Pockros, P., Reddy, K.R., Mantry, P.S., Cohen, E., Bennett, M., Sulkowski, M., et al. RUBY-I: Ombitasvir/paritaprevir/ritonavir + dasabuvir ± RIBAVIRIN in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease. Hepatology, 2015 Abstract The Liver Meeting (AASLD), San Francisco, CA.
40. [40] Jacobson, I.M., Pawlotsky, J.M., Afdhal, N.H., Dusheiko, G.M., Forns, X., Jensen, D.M., et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 19 (2012), 1–26.
41. [41] Poordad, F., Sievert, W., Mollison, L., Bennett, M., Tse, E., Brau, N., et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 313 (2015), 1728–1735.
42. [42] EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
43. [43] O'Brien, T.R., Feld, J.J., Kottilil, S., Pfeiffer, R.M., No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with HCV RNA <6,000,000 IU/ml. Hepatology, 2015.
44. [44] van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G.S., Khoo, S., et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 61 (2015), 1174–1182.
45. [45] Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., Taylor, L.E., Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
46. [46] Grebely, J., Dore, G.J., Greenwald, R., Swan, T., Barua, S., Taylor, L.E., Hepatitis C virus treatment and persons who inject drugs. Ann Intern Med, 164, 2016, 203.
47. [47] Wedemeyer, H., Dore, G.J., Ward, J.W., Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat 22 (2015), 1–5.
48. [48] EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
49. [49] Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
50. [50] Roth, D., Nelson, D.R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H. Jr., et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
51. [51] Zeuzem, S., Ghalib, R., Reddy, K.R., Pockros, P.J., Ben Ari, Z., Zhao, Y., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
52. [52] Muir, A.J., Strasser, S., Wang, S., et al. High SVR rate with ABT-493+ABT530 for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection. Gastroenterology, 150, 2016, S1047.
53. [53] Desnoyer, A., Pospai, D., Le, M.P., Gervais, A., Heurgue-Berlot, A., Laradi, A., et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65 (2016), 40–47.
54. [54] Nazario, H.E., Ndungu, M., Modi, A.A., Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int 36 (2016), 798–801.
55. [55] Saxena, V., Koraishy, F.M., Sise, M.E., Lim, J.K., Schmidt, M., Chung, R.T., et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36 (2016), 807–816.
56. [56] Foster, G.R., Afdhal, N., Roberts, S.K., Brau, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
57. [57] Gane, E., Nguyen, M., Kwo, P., Kowdley, K.V., Reau, N., Jacobson, I., et al. Short-duration treatment with sofosbuvir/velpatasvir plus GS-9857 in treatment-naïve genotype 1–6 HCV-infected patients with or without cirrhosis. J Hepatol, 2016 Abstract 138.
58. [58] Gane, E., Poordad, F., Wells, J.T., Hyland, R., Yang, Y., Dvory-Sobol, H., et al. High efficacy of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1–6 HCV infected patients including those previously treated with direct-acting antivirals. J Hepatol, 2016 Abstract PS008.
59. [59] Ng, T., Krishnan, P., ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance. Hepatology, 2015 Abstract The Liver Meeting (AASLD), San Francisco, CA.
60. [60] Poordad, F., Felizarta, F., Asatryan, A., Hassanein, T., Aguilar, H., Lalezari, J., et al. 100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naïve or -experienced patients with the combination of ABT-493 and ABT-530 for 8 weeks (SURVEYOR-I) [8 weeks]. Hepatology, 2015.
61. [61] Kwo, P., Bennett, M., Wang, S., Vargas, H.E., Wyles, D., Overcash, J.S., et al. SURVEYOR-II: High SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-naïve and treatment-experienced patients with HCV genotype 3 infection. Hepatology, 2015 Abstract The Liver Meeting (AASLD), San Francisco, CA.
62. [62] Kwo, P., Wyles, D., Wang, S., Poordad, F., Gane, E., Maliakkal, B., et al. 100% SVR with ABT-493 and ABT-530 with or without ribavirin in treatment-naive HCV genotype 3-infected patients with cirrhosis. J Hepatol, 2016 Abstract LB-01.
63. [63] Caro, L., Du, L., Huang, S.P., Wenning, L., Su, J., Hwang, P., et al. Relationship Between Transaminase Levels and Plasma Pharmacokinetics Following Administration of MK-5172 With Pegylated Interferon Alfa-2b and Ribavirin to HCV Genotype 1 Treatment-Naïve Patients. J Hepatol, 2013 Abstract International Liver Congress (EASL), Amsterdam, Netherlands.
64. [64] Poordad, F., Lawitz, E., Gutierrez, J.A., Evans, B., Howe, A., Hwa-Ping, F., et al. C-SWIFT: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol, 2015 Abstract International Liver Congress (EASL), Vienna, Austria.
65. [65] Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
66. [66] Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
67. [67] Cheung, M., Foster, G.R., Irving, W., Walker, A.J., Hudson, B., Verma, S., et al. Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/daclatasvir with or without ribavirin - 6 and 12 month outcomes compared to untreated patients. J Hepatol, 2016 Abstract PS097.
68. [68] Welzel TM, Herzer K, Ferenci P, Petersen J, Gschwantler M, Cornberg M, Berg T, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program international liver congress, European Association for the Study of the Liver 2015, Vienna, Austria, 2015.
69. [69] Pol, S., Bourliere, M., Lucier, S., de Ledinghen, V., Zoulim, F., Dorival, C., et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER. J Hepatol, 2015 Abstract International Liver Congress (EASL), Vienna, Austria.
70. [70] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
71. [71] Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
72. [72] Tran, T.T., Morgan, T.R., Thuluvath, P.J., Etzkorn, K., Hinestrosa, F., Tong, M., et al. Safety and efficacy of treatment with sofosbuvir + GS-5816 ± ribavirin for 8 or 12 weeks in treatment-naïve patients with genotype 1–6 HCV infection. Hepatology, 2014 Abstract The Liver Meeting (AASLD), Boston, MA.
73. [73] Gane, E.J., Hyland, R., Ying, Y., Svarovskaia, E., Stamm, L.M., Brainard, D., et al. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naïve and DAA-experienced genotype 1 patients with and without cirrhosis. J Hepatol, 2015 Abstract International Liver Congress, Vienna, Austria.
74. [74] Lau, G.K., Benhamou, Y., Chen, C., Schinazi, R.F., Complete cure after three weeks of all-oral triple-direct acting antiviral (DAA) regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI STUDY). Hepatology, 2015 Abstract The Liver Meeting (AASLD). San Francisco, CA. Abstract LB-32.
75. [75] Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 368 (2013), 1685–1694.
76. [76] Van Der Ree, M., de Vree, M.L., Stelma, F., Willemse, S., ven der Valk, M., Rietdijk, S., et al. A single dose of RG-101, a GalNAc-conjugated oligonucleotide targeting mir-122, results in undetectable HCV RNA levels in chronic hepatitis C patients at week 28 of follow-up. Hepatology, 2015 Abstract The Liver Meeting (AASLD), San Francisco, CA.
77. [77] Horvath, G., Papatheodoridis, M., Fabri, M., Makara, M., Grint, P., Huang, M., et al. RG-101 in combination with 4 weeks of oral diract acting antiviral therapy achieves high virologic response rates in treatment-naive gneotype 1 and 4 chronic hepatitis C patients: interim results from a randomised, multicenter, phase 2 study. J Hepatol, 2016 Abstract GS08.
78. [78] Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
79. [79] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
80. [80] Xue, W., Ban, Y., Liu, H., Yao, X., Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model 54 (2014), 621–633.
81. [81] Sun, J.H., O'Boyle, D.R. 2nd, Fridell, R.A., Langley, D.R., Wang, C., Roberts, S.B., et al. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. Nature 527 (2015), 245–248.
82. [82] Lawitz, E., Flamm, S.L., Yang, J.C., Pang, P.S., Zhu, Y., Svarovskaia, E., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with Ledipasvir/Sofosbuvir for 24 weeks. J Hepatol, 62, 2015, O005.
83. [83] Lawitz, E., Poordad, F., Gutierrez, J.A., Wells, J.T., Landaverde, C.E., Reiling, J.R., et al. C-SWIFT retreatment (Part B): 12 weeks of elbasvir/grazoprevir with sofosbuvir and ribavirin successfully treated G1-infected subjects who failed short-duration all-oral therapy. Hepatology, 2015 Abstract The Liver Meeting (AASLD). San Francisco, CA.
84. [84] Poordad, F., Gordon, S., Asatryan, A., Felizarta, F., Reindollar, R., Landis, C., et al. High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antviral-containing regimens: The Magellan-I Study. J Hepatol, GS11, 2016.